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Introduction {#sec1}
============

Congenital heart diseases (CHDs) are prenatal defects that affect the heart\'s structure and/or function and are the leading cause of infant mortality under 1 year of age. Approximately 1%--2% of human babies are born with cardiac malformations that pose as major risk factors for adult cardiovascular problems ([@bib4], [@bib38]). The heart, the first functional organ in the developing embryo, starts to form early on during development, before the end of gastrulation. The first and second heart fields (FHF and SHF, respectively) as well as the proepicardial organ and the cardiac neural crest are the major contributors to the forming heart ([@bib33]). The FHF gives rise primarily to the left ventricle and most of the atria; the SHF contributes to the right ventricle, outflow tract, and parts of the atria ([@bib53], [@bib61]). Induction of the cardiac fate and the proper morphogenesis of the vertebrate heart are controlled by a well-characterized and highly conserved combinatorial network of transcription factors and signaling molecules that act together to orchestrate the embryonic development of the four-chambered mammalian heart and the subsequent post-natal maturation. Of important note, the adult heart has minimal intrinsic regenerative capacity ([@bib34]). As a result, significant stressors on the heart can result in loss of viable or functional myocardial tissue and ultimately heart failure. This renders cardiovascular disease a leading cause of death worldwide and highlights an unmet clinical need for novel approaches for heart regeneration. One major approach is the use of stem cells that can be induced to give rise to the different cell types that constitute the heart. Understanding the cellular processes and signaling pathways that govern *in vivo* heart formation and maturation is necessary for the generation of functional mature cardiac tissue for clinical and preclinical applications ([@bib19]).

Targeted protein degradation by the ubiquitin proteasome system (UPS) is important for the regulation of cellular physiology and is required for normal organ formation ([@bib16]). The UPS consists of three enzymes: Ubiquitin (Ub) activating enzyme, E1, which transfers activated Ub to the Ub conjugating enzyme, E2. This then interacts with the E3 Ub ligase that covalently links the Ub or Ub chain to a lysine residue in the substrate thus targeting it for degradation by the proteasome. The E3 Ub ligase is responsible for substrate specificity ([@bib20]). Recent evidence points to a role of the UPS in heart disease, particularly in myocardial remodeling, familial cardiomyopathies, chronic heart failure, and ischemia-reperfusion injury ([@bib41]). Pharmacological inhibition of the proteasome is a new and promising means for cardioprotection ([@bib41]). Paradoxically, enhancing UPS activity has in some cases also provided protection against heart disease ([@bib5], [@bib29], [@bib44]) highlighting the importance of defining the role of the UPS as a therapeutic target in cardiac disease. In addition to its role as a protein quality control, the UPS has also been shown to regulate the turnover of sarcomere proteins, including the myofibrillar proteins myosin, actin, and troponin. Examples of this include the E3 Ub ligases MuRF1 (muscle-specific RING finger 1, targeting troponin I) and F box protein Fbx122 (targeting α-actinin and filamin C) ([@bib21], [@bib51]). E3 ligases have also been shown to regulate important signaling pathways in the heart, such as the JNK (c-Jun N terminal kinase) ([@bib25]), calcineurin ([@bib11]), and the VEGF (vascular endothelial growth factor) signaling pathways ([@bib37]). This important role of the UPS in the heart and its potential for a therapeutic target in cardiac disease brings about a need to understand its specific function in heart development and disease. Using our previously described transgenic reporter system ([@bib10]), we identified Asb2 (ankyrin repeat-containing protein with a suppressor of cytokine signaling box \[SOCS box\] 2) as being enriched in FHF and SHF cardiac progenitors. Asb2, which encodes specificity subunit of Cullin 5 RING E3 Ub ligase, exists in two isoforms: Asb2α and Asb2β in mouse, corresponding to variants 2 and 1 in humans, respectively ([@bib3]). It has previously been shown to regulate differentiation of myeloid leukemia cells and skeletal myogenesis through proteasomal degradation of filamin proteins ([@bib3], [@bib17], [@bib18]). Filamins (Flna, Flnb, and Flnc in mice) are actin-binding proteins important for the stabilization of the actin-cytoskeleton ([@bib58]). Flnc is the only isoform expressed in the heart muscle where it is required for normal contractility ([@bib13]). Flna expression in the heart is restricted to endocardial and mesenchymal cells of the cardiac cushions during development and to valve leaflets in the adult heart ([@bib39]). FLNA and FLNC mutations have been linked to cardiac defects in humans ([@bib8], [@bib9], [@bib24], [@bib57]). In zebrafish, an additional Asb2 target TCF3 was very recently identified where TCF3 was negatively regulated by Asb2 during cardiogenesis ([@bib14]). Asb2 downregulation was also shown to be a mediator of follistatin-induced muscle hypertrophy and SMAD2/3 regulation of skeletal muscle mass in young adults in mice. The repression of Asb2 was, however, ameliorated in aging mice, some of which also displayed increasing Asb2 baseline levels ([@bib7]). Asb2 overexpression was also shown to drive skeletal muscle atrophy in mice ([@bib7]). A recent study also showed that Asb2 knockout is embryonic lethal and that Asb2α targets Flna for proteasomal degradation during early cardiomyocyte differentiation ([@bib35]). The embryonic lethality of Asb2 mutants was shown to be primarily due to heart defects ([@bib35]).

Herein, we show that Asb2 knockout in the FHF and SHF are both embryonic lethal by E10.5 and E12.5, respectively. Using tissue clearing combined with immunofluorescence technique, we show that Asb2 mutant hearts have incomplete looping. Moreover, Asb2 regulates cardiac morphogenesis partly through Flna turnover, and we hereby propose a model where Asb2-Flna controls TGFβ-SMAD signaling to drive early cardiac formation. Additionally, Asb2 lethality in the anterior heart field (AHF) is partially rescued by Flna removal from these hearts. We also show that Asb2 ablation in the AHF leads to double outlet right ventricle (DORV), which is corrected upon further deletion of Flna from these hearts. Finally, we reveal that Asb2 role in cardiomyocyte differentiation is conserved in human cardiomyocytes as well. Collectively, our results shed light on the UPS regulation of heart development and its role as a cardio-therapeutic target and provide evidence for the first time for the role of the UPS in the rare congenital heart defect, DORV.

Results {#sec2}
=======

Asb2 Is Highly Enriched in the Embryonic Heart {#sec2.1}
----------------------------------------------

We have previously characterized a transgenic reporter system for the isolation of three distinct mouse cardiac progenitor cells from developing embryos: FHF population, marked by Nkx2.5+.Mef2c- expression, and two SHF population subsets: Nkx2.5-.Mef2c+ and Nkx2.5+.Mef2c+ ([@bib10]). Genome-wide transcriptional profiling and real-time PCR (qPCR) reveal Asb2 transcripts enrichment in the three populations ([Figure 1](#fig1){ref-type="fig"}A) ([@bib10]). To investigate the temporal expression of Asb2 in the developing heart, we performed qPCR analysis on RNA from mouse hearts at different stages of embryonic development. Our data show that Asb2α is expressed similarly throughout heart development, whereas Asb2β expression increases with development ([Figure 1](#fig1){ref-type="fig"}B). This is further confirmed by western blot analysis, which shows that the Asb2 band in the embryonic heart co-migrates with that in the spleen (which expresses Asb2α \[[@bib52]\]), whereas the Asb2 band in the adult heart co-migrates with that in the skeletal muscle (known to express Asb2β \[[@bib3]\]) ([Figure 1](#fig1){ref-type="fig"}C). To further investigate *in vivo* spatial cardiac expression of Abs2, we performed *in situ* hybridization on E9.5 embryos. Our data reveal robust expression of Asb2 transcripts predominantly in the left (LV) and right ventricles (RV) and to a lower extent in inflow (IFT) and outflow tracts (OFT) ([Figure 1](#fig1){ref-type="fig"}D). Furthermore, immunostaining of E10.5 and E11.5 ([Figure 1](#fig1){ref-type="fig"}E, upper and lower panels, respectively) embryonic sections using Asb2-specific antibody shows that, in the heart, Asb2 expression (green) is restricted to the myocardium overlapping with cardiac Troponin T (red). White arrows in the zoomed merged image at E10.5 (right panel) indicate overlap of Asb2 and Troponin T in the myocardial layer, but no expression is seen in the endocardial layer indicated by arrow heads.Figure 1Asb2 Is Expressed in the Developing and Adult Heart and Undergoes Isoform Switching during Differentiation(A) qPCR analysis of embryonic cardiomyocytes reveals predominant Asb2α expression in the R-G+ and the R+G+ populations. R-G+: Mef2c-.Nkx2-5+; R+G+: Mef2c+.Nkx2-5+; R+G-: Mef2c+.Nkx2-5-; NEG: Mef2c-.Nkx2-5-.(B) qPCR analysis of Asb2α and Asb2β on RNA from murine hearts of different embryonic stages as well as neonates and postnatal day 8--9. Note that the α isoform is equally expressed at all stages, whereas the β isoform expression increases with development.(C) Western blot analysis on whole tissue extracts from embryonic and adult heart, spleen, and skeletal muscle using Asb2-specific antibody. Note that Asb2 corresponding band in the embryonic heart co-migrates with that in the spleen where only the α isoform is expressed, whereas that in the adult heart co-migrates with that in the skeletal muscle that is known to express on the β isoform. These data are consistent with the qPCR data in (B).(D) *In situ* hybridization on E9.5 mouse embryo showing robust Asb2 expression in the LV, RV, and OFT and to a lesser extent the IFT. LV, left ventricle; RV, right ventricle; OFT, outflow tract; IFT, inflow tract.(E) Immunohistochemistry on E10.5 and E12.5 mouse embryos using Asb2-specific antibody (green) and Troponin T (red). DAPI (blue) marks nuclei. Note Asb2 expression colocalizes with Troponin T in the myocardium (arrows) and no expression is seen in the endocardial cells (arrow heads). Scale bar is equivalent to 250 μm in the first three heart images left to right at E10.5 (top) and E12.5 (bottom), 25 μm in the E10.5 heart image top far right, and 50 μm in the E12.5 heart image bottom far right as indicated in the figure.

Asb2 Is Required for Early Cardiac Formation {#sec2.2}
--------------------------------------------

To investigate the role of Asb2 during cardiac development, we generated two conditional knockout lines (KO): Nkx2-5^+/Cre^ (a mouse line with the Cre recombinase knocked into the Nkx2-5 locus) and AHF-Cre (a mouse line with a transgene placing Cre under the transcriptional control of the AHF enhancer of the Mef2c gene). These mouse lines allow for the targeted removal of ([@bib31]) Asb2 from the whole heart and the SHF, respectively ([@bib31]). The floxed alleles are in common region and inactivate both Asb2 isoforms. Both conditional KOs have pericardial edema and are embryonic lethal: Nkx2-5^+/Cre^.Asb2^fl/fl^ mice die at E10.5--11 and AHF-Cre.Asb2^fl/fl^ die at E11.5--12 ([Figures 2](#fig2){ref-type="fig"}A and 2B, respectively). AHF-Cre.Asb2^fl/fl^ mice analyzed at E10.5 also have shorter OFT compared with their control littermates ([Figure S1](#mmc1){ref-type="supplementary-material"}D). For Nkx2-5^+/Cre^.Asb2^fl/fl^, mice were analyzed at E8.5 (3 litters), E9.5 (23 litters), E10.5 (3 litters), and E11.5 (2 litters); for AHF-Cre.Asb2^fl/fl^, mice were analyzed at E9.5 (3 litters), E10.5 (4 litters), and E12.5 (2 litters). Each litter consists of 8--11 embryos in total. All embryos were genotyped. [Figure S1](#mmc1){ref-type="supplementary-material"}A shows the reduced level of Asb2 in the heterozygotes (Nkx2-5^+/Cre^.Asb2^fl/+^) and the complete loss of Asb2 in the knockouts (Nkx2-5^+/Cre^.Asb2^fl/fl^).Figure 2Asb2 Is Essential for Early Cardiac Development(A) Nkx2-5^+/Cre^.Asb2 E9.5 and E11.5 knockout (KO) embryos (fl/fl) versus wild-type littermates (Wt). Note the resorbing KO embryo at E11.5. Scale bar is equivalent to 0.4 mm for E9.5 and 0.5 mm for E11.5 as indicated.(B) AHF-Cre.Asb2 E10.5 and E12.5 knockout (KO) embryos (fl/fl) versus wild-type littermates (Wt). Note the resorbing KO embryo at E12.5. Scale bar is equivalent to 0.5 mm for E10.5 and E12.5 as indicated in the figure.(C) 3D reconstruction of CUBIC-cleared, Troponin-T-stained E9.5 whole control and Asb2 mutant embryos showing both ventral and dorsal views. Note the bulging in the right ventricle of the control heart that is lacking in the mutant (indicated by the red arrow heads). Scale bar is equivalent to 200 μm as indicated.(D) Measurement of the heart tube of control and Asb2 mutant hearts. Note the statistically significant shorter heart tubes of the mutants. N = 5 per group. Data are represented as mean ± SEM. ∗ = p \< 0.005. Unpaired t test was used using GraphPad Prism; p \< 0.05 is considered statistically significant.(E) Heatmap analysis of a subset of cardiac looping differentially expressed genes in RNA-seq data from control (Nkx2-5^+/Cre^.Asb2^fl/+^) versus Nkx2-5^+/Cre^.Asb2 knockout E9.5 murine hearts. N = 3 in each group (each sample is in itself a combination of three to four hearts to account for heterogeneity among different litters).

In order to perform a phenotypic analysis of the Nkx2-5^+/Cre^-Asb2^fl/fl^ mutant embryos, we used state-of-the-art tissue clearing technique CUBIC combined with immunostaining. CUBIC can effectively clear mice embryos and embryonic hearts while preserving immunolabels ([@bib23], [@bib54]). Nkx2-5^+/Cre^-Asb2^fl/fl^ and control littermates e9.5 mice embryos were cleared with CUBIC and stained for Troponin T to mark cardiomyocytes as well as DAPI for nuclei. Confocal microscopy with optical sectioning followed by 3D-reconstruction allowed the precise visualization of the developing hearts without disruption of underlying anatomy. During cardiac morphogenesis, the straight heart tube undergoes sequential looping steps to get to the fully looped heart. The fully looped heart acquires a helical shape in mice that is also referred to as the mature S-loop in chicks ([@bib28], [@bib32]). In Le Garrec et al. paper, they used computer modeling to simulate the biological process of mouse cardiac looping, incorporating in their model the left-right asymmetry and mechanical constraints seen in the looping heart. Their findings suggest that the lack of any of these parameters would lead to a C-shaped heart loop rather than the helical structure. In the chick, the heart is first transformed into a C-shaped heart, a process known as dextral looping. The C-loop is then converted into an immature S-loop that then transforms into a mature S-looped heart where the ventricular segments are curved outward to generate the left and right chambers ([@bib32]). As shown in [Figure 2](#fig2){ref-type="fig"}C, the mutant embryos do not form the full helical structure seen in the control littermates. Instead, they have partially looped hearts that resemble the C-shaped hearts in the chick ([@bib32]). Moreover, measurement of the heart tube length in mutant versus control hearts reveals statistically significant shorter tubes in the mutant hearts ([Figure 2](#fig2){ref-type="fig"}D). [Video S1](#mmc5){ref-type="supplementary-material"} is a z stack of stained control and mutant e9.5 embryos showing the incomplete looping in the mutant embryo. [Figure S1](#mmc1){ref-type="supplementary-material"}C represents four images from the z stack at different depth in the embryo. Four to five embryos were analyzed for each condition. The efficiency of the CUBIC/immunostaining technique on e9.5 mouse embryo is evidenced by the clearly visible striations of the cardiac muscle fibers ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

Video S1. 90-120 Serial z stacks of Control (Left) versus Mutant (Right) e9.5 Mice Hearts That Have Been Cleared and Stained with Troponin T, Related to Figure 2Blue is DAPI to mark nuclei. A, primitive atrium; AVC, atrioventricular canal; LV, primitive left ventricle; RV, primitive right ventricle; OFT, outflow tract. The arrow indicates the direction of looping. Notice the bulging in the control heart to form the S-shaped looped heart that is missing in the mutant.

In order to identify Asb2 downstream targets in the heart, RNA sequencing (RNA-seq) analysis was performed on Nkx2-5^+/Cre^.Asb2^fl/fl^ and control littermates ([Figure 3](#fig3){ref-type="fig"}B) ([Figure S2](#mmc1){ref-type="supplementary-material"}C shows reduced levels of Asb2 transcripts in the Nkx2-5^+/Cre^.Asb2^fl/fl^ knockout compared with the Nkx2-5^+/Cre^.Asb2^fl/+^ heterozygote control). The gene expression profile was greatly altered in the Asb2 mutant hearts compared with their control littermates (Group 2 versus Group 1) ([Figure 3](#fig3){ref-type="fig"}B). Of note, a number of genes that are mis-expressed in the Asb2 cardiac mutant hearts have been previously linked to abnormal cardiac looping in mice ([Figure 2](#fig2){ref-type="fig"}E) ([@bib1], [@bib2], [@bib6], [@bib28], [@bib36], [@bib47], [@bib59]). Ingenuity Pathway Analysis also shows that "cardiovascular system development and function" as well as "cardiovascular disease" are among the top pathways altered in the Asb2 mutant hearts ([Table S1](#mmc2){ref-type="supplementary-material"}, yellow highlights). [Table S2](#mmc3){ref-type="supplementary-material"} is an upstream analysis with the ones with a positive activation *Z* score \> 1.5 highlighted in yellow. This list shows the pathways whose downstream targets are altered (upregulated or downregulated) in our knockouts versus controls. Targets with a positive *Z* score suggest upregulation pathways in the Asb2 mutant hearts.Figure 3Asb2 Targets Flna for Proteasomal Degradation in the Developing Heart and Asb2-Mutant Hearts Have an Altered Gene Expression Profile(A) Immunohistochemistry on E9.5 Abs2 heterozygote (Nkx2-5^+/Cre^.Asb2^fl/+^, middle pane) and mutant hearts (Nkx2-5^+/Cre^.Asb2^fl/fl^, lower panel) as well as Wt controls (top panel) using Flna (red) and Troponin-T (green)-specific antibodies. Note that FlnA expression is restricted to the endocardial layer (white arrow heads) in the Wt heart, whereas it is abnormally expressed in the myocardial layer in the Asb2-mutant hearts co-localizing with Troponin-T expression there (white arrows). Moreover, some cardiomyocytes in the outflow tract of the Asb2-heterozygous hearts also express Flna (yellow arrows) suggesting a dose-dependent regulation. Scale bar is equivalent to 250 μm in the first column (left), 100 μm in the second, third, and fourth columns, and 25 μm in the fifth (far right) column as indicated in the figure.(B) Heatmap analysis of RNA-seq data from control (Group1: Nkx2-5^+/Cre^.Asb2^fl/+^), Asb2 mutant (Group2: Nkx2-5^+/Cre^.Asb2^fl/fl^), Flna mutant (Group3: Nkx2-5^+/Cre^.Flna^fl/y^), and Asb2-Flna double mutant (Group4: Nkx2-5^+/Cre^.Asb2^fl/fl^.Flna^fl/y^) E9.5 murine hearts. Note the high level of differentially expressed genes in the Asb2-mutant and Asb2-Flna double mutant versus the control groups. A small subset of genes (indicated by arrows) that are perturbed in the Asb2-mutant hearts are restored to normal in the Asb2-Flna double mutants. N = 3 in each group (each sample is in itself a combination of three to four hearts to account for heterogeneity among different litters).(C) Heatmap analysis of a subset of genes from the RNA-seq data in (B) that are part of the Tgfβ/Smad signaling pathway. Note that the Foxa genes expression levels (indicated with a yellow line) that are downstream of the Tgfβ/Smad are restored to normal in the Asb2-Flna double mutants versus the Asb2-mutant hearts.

Asb2 Controls Cardiac Morphogenesis Partly through Regulating Filamin A {#sec2.3}
-----------------------------------------------------------------------

Since Asb2 targets filamin proteins for degradation ([@bib35]) and Flna perturbations lead to cardiac defects and embryonic lethality ([@bib12]), we investigated cardiac Flna expression in the Nkx2-5^+/Cre^.Asb2^fl/fl^. Flna expression in the control heart ([Figure 3](#fig3){ref-type="fig"}A, top panel) is restricted to endocardial and pericardial layers (red staining, white arrow heads). In the knockout embryos ([Figure 3](#fig3){ref-type="fig"}A, third panel), Flna\'s expression domain is abnormally expanded to include the myocardial layer (white arrows), co-localizing with Troponin T expression (green for Troponin and yellow for the co-localization). Moreover, in Nkx2-5^+/Cre^.Asb2^fl/+^ heterozygous hearts ([Figure 3](#fig3){ref-type="fig"}A, second panel), Flna is abnormally expressed in some cardiomyocytes of the OFT myocardium (yellow arrows) suggesting that Asb2 regulation of Flna turnover is dose dependent. We then hypothesized that, if Asb2 cardiac mutant phenotype is due to overexpression of Flna, then concurrently deleting Flna along with Asb2 should suppress the Asb2 phenotype. (Please note that Flna is an x-linked gene so a knockout is denoted by fl/fl for female or fl/y for male, whereas a heterozygous is denoted by fl/x or fl/+.) To examine this hypothesis, we developed Nkx2-5^+/Cre^.Asb2^fl/fl^.Flna^fl/y^ double mutants. Removal of Flna from the hearts of Nkx2-5^+/Cre^.Asb2^fl/fl^ did not rescue lethality ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Approximately 16 litters were analyzed at E9.5 and 3 litters at E10.5. As expected, Nkx2-5^+/Cre^.Asb2^fl/fl^.Flna^fl/fl^ double knockouts no longer harbor ectopic Flna expression in the myocardium ([Figure S2](#mmc1){ref-type="supplementary-material"}B) as was previously seen with the Nkx2-5^+/Cre^.Asb2^fl/fl^ single knockouts ([Figure 3](#fig3){ref-type="fig"}A). Instead, the double knockouts have normal endocardial expression of Flna similar to their control littermates ([Figure S2](#mmc1){ref-type="supplementary-material"}B). RNA-seq analysis on e9.5 hearts from these mice show that their gene expression profile is closely related to the Nkx2-5^+/Cre^.Asb2^fl/fl^ group (Group 2 versus Group 4) ([Figure S2](#mmc1){ref-type="supplementary-material"}C shows reduced levels of Asb2 transcripts in the Nkx2-5^+/Cre^.Asb2^fl/fl^.Flna^fl/y^ double knockout compared with the Nkx2-5^+/Cre^.Asb2^fl/+^ heterozygote control). However, some genes whose expression was altered in the Nkx2-5^+/Cre^.Asb2^fl/fl^ group are restored to normal in the Nkx2-5^+/Cre^.Asb2^fl/fl^.Flna^fl/y^ hearts (indicated by arrows and shown in [Table S3](#mmc4){ref-type="supplementary-material"}). These results suggest that Flna concurrent deletion can restore the normal expression level of a subset of genes in the Asb2 mutant hearts. Among these genes are the Foxa genes, which are downstream of the Tgfβ/Smad signaling ([Figure 3](#fig3){ref-type="fig"}C, yellow line) ([@bib55]). Other genes in the Tgfβ/Smad pathway are also altered in both Asb2-mutant and Asb2.Flna double mutant hearts ([Figure 3](#fig3){ref-type="fig"}C). [Figure S2](#mmc1){ref-type="supplementary-material"}D is a qPCR analysis confirming some of these altered genes. Tgfβr1 and InhA (which encodes a member of the Tgfβ superfamily) are also among the positively regulated targets in the upstream analysis of the RNA-seq data of Asb2-mutant hearts versus control ([Table S2](#mmc3){ref-type="supplementary-material"}). Both genes are no longer positively regulated in the upstream analysis of the list of genes corrected in the Asb2-Flna double mutant hearts ([Table S3](#mmc4){ref-type="supplementary-material"}, yellow highlights). These data prompted further analysis of the Asb2/Flna regulation of TGFβ/Smad signaling in the heart of these mice.

Asb2 Regulates TGFβ/Smad Signaling through Regulating Filamin A Protein {#sec2.4}
-----------------------------------------------------------------------

TGFβ signaling is initiated upon ligand-stimulated activation of serine/threonine receptor kinases that in turn lead to phosphorylation and activation of Smad proteins. Activated Smads interact with common signaling transducer Smad4, translocate to the nucleus, and activate downstream targets ([@bib50]). Flna directly associates with Smad2 and Smad2 phosphorylation, and TGFβ/Smad2 signaling is impaired in Fln-null human melanoma cells ([@bib49], [@bib62]). Moreover, FLNA mutations were linked to x-linked myxomatous valvular dystrophy, a multivalve degeneration disorder, and disrupted TGFβ/Smad2/3 signaling was implicated in the disease pathogenesis ([@bib15], [@bib39]). Using the "Build Network" module in MetaCore Clarivate Analytics software, we investigated the Asb2-Flna-Smad2 interaction. As shown in [Figure 4](#fig4){ref-type="fig"}A, Asb2 negatively regulates Flna through ubiquitination and Flna positively regulates Smad2 through direct binding. Asb2, Flna, and Smad2 are shown in red for visualization. In order to investigate further Asb2/Flna regulation of TGFβ/Smad2 signaling in cardiac development, we immunostained E9.5 Asb2-mutant hearts with antisera directed against pSmad2 ([Figure 4](#fig4){ref-type="fig"}B) and then quantified the pSmad2-positive nuclei. [Figure 4](#fig4){ref-type="fig"}C shows significant increase in the percentage of pSmad2-positive nuclei in the Nkx2-5^+/Cre^.Asb2^fl/fl^ myocytes (previously shown to have overexpression of Flna \[[Figure 3](#fig3){ref-type="fig"}A\]) compared with their littermate controls. This increase was not seen in the endocardial cells where Flna expression is normal ([Figure 3](#fig3){ref-type="fig"}A). Interestingly, pSmad2 levels were restored to normal in the Nkx2-5^+/Cre^.Asb2^fl/fl^.Flna^fl/fl^ (double mutant) myocytes further confirming that Asb2 regulates pSmad2 in the heart through the regulated turnover of Flna.Figure 4Tgfβ/Smad Signaling Activity Is Downstream Asb2-Flna in the Developing Heart(A) Schematic representation of Asb2-Flna-Smad2 interaction network using MetaCore Clarivate Analytics software. Note that Asb2 ubiquitinates and negatively regulates Flna, whereas Flna binds directly to and positively regulates Smad2.(B) Immunohistochemistry on Nkx2-5^+/Cre^.Asb2 mutant (middle panel) and Nkx2-5^+/Cre^.Asb2-Flna double mutant (last panel) murine hearts as well as wild-type controls (top panel) using pSmad2-specific antibody (green) and Troponin T (red). Note the nuclear localization of pSmad2 as a sign of Tgfβ/Smad2 cycle activation. Examples of positive (purple arrowhead) and negative (yellow arrowheads) nuclei are indicated in the Wt sample (red box). DAPI marks all nuclei (AV, atrioventricular canal; V, primitive ventricle; OFT, outflow tract; Myo, myocytes; Endo, endocardial cells). Myocardial cells are marked by white arrows; endocardial cells are marked by white arrowheads. Scale bar is equivalent to 75 μm in the first two columns from the left and 25 μm in the third, fourth, and fifth columns as indicated in the figure.(C) Quantification of the immunostaining in (B) of percentage of pSmad2-positive nuclei in cardiomyocytes ((AV+V) Myo and OFT Myo) as well as endocardial cells (AV endo). Note the increased level of pSmad2-positive nuclei in Asb2-mutant myocytes that are restored to normal in the Asb2-FlnA double mutants. This regulation is not seen in the endocardial cells that do not express Asb2 ([Figure 1](#fig1){ref-type="fig"}E). n = 7 for Wt; n = 4 for Nkx2-5^+/Cre^.Asb2^fl/fl^; n = 3 for Nkx2-5^+/Cre^.Asb2^fl/fl^.Flna^fl/fl^. Data are represented as mean ± SEM. ∗ = p \< 0.05 Control versus Nkx2-5^+/Cre^.Asb2^fl/fl^; \# = p \< 0.05 Nkx2-5^+/Cre^.Asb2^fl/fl^ versus Nkx2-5^+/Cre^.Asb2^fl/fl^.Flna^fl/fl^; NS = not significant. Two-way ANOVA was used for analysis using GraphPad Prism. p \< 0.05 is considered statistically significant.

Flna Removal from AHF-Cre.Asb2 Mutant Hearts Partially Rescues Embryonic Lethality {#sec2.5}
----------------------------------------------------------------------------------

To examine Flna expression in the AHF-Cre.Asb2^fl/fl^ hearts (where Asb2 is knocked out in the RV and OFT only), Flna immunostaining was performed. As shown in [Figure 5](#fig5){ref-type="fig"}A, Flna expression (red) is restricted to the endocardial and epicardial layers in the control hearts (top panel, white arrow heads), whereas it is aberrantly expressed in the myocardial layer of the OFT and RV only (red staining lower panel, white arrows), co-localizing with TroponinT expression (yellow staining lower panel) there. Flna expression was normal in the myocardial layer of the primitive left ventricle (PV) that harbors normal Asb2 expression and acts as an internal control in these mice. We then sought to examine the effect of further knocking out Flna from the AHF-Cre.Asb2-mutant hearts. To do this, we crossed Asb2^fl/fl^.Flna^fl/fl^ with AHF-Cre.Asb2^fl/+^ mice. Our results show that AHF-Cre.Asb2^fl/fl^.Flna^fl/y^ are born with the expected Mendelian ratios ([Figure 5](#fig5){ref-type="fig"}B); however, newborn pups die between P0.5 and P1.5. These results show that Flna deletion partially rescues Asb2 lethality. The AHF-Cre.Asb2^fl/fl^.Flna^fl/+^ also survive to birth albeit at a lower percentage from what is expected by Mendelian ratios; these mice also die right after birth at P0.5.Figure 5Flna Removal from AHF^Cre^.Asb2 Mutant Hearts Partially Rescues Their Lethality(A) Immunohistochemistry on E9.5 AHF-Cre.Abs2 mutant hearts (AHF-Cre.Asb2^fl/fl^, lower panel) and littermate controls (AHF-Cre.Asb2^fl/+^, top panel) using Flna (red)- and Troponin-T (green)-specific antibodies. Note overexpression of Flna in the OFT (white arrows) of the AHF-Cre.Asb2 mutant hearts but not the primitive left ventricle (PV) that harbors normal Asb2 levels thus serving as an internal control. Flna expression in the control hearts is restricted to the endocardial layer (white arrow heads). Scale bar is equivalent to 250 μm in the first column (left); 100 μm in the second, third, and fourth columns; 25 μm in the fifth column (far right) as indicated.(B) Table showing the survival of AHF-Cre.Asb2 mutant (top) and AHF-Cre.Asb2-Flna double mutant (bottom) mice. Note that no AHF-Cre.Abs2 mutant mice are observed at P0.5. However, the AHF-Cre.Asb2-Flna double mutant (Asb2^fl/fl^.Flna^fl/y^) mice are born at the expected Mendelian ratios. AHF-Cre.Asb2-mutant mice harboring one copy of Flna (Asb2^fl/fl^.Flna^fl/+^) are also born yet at lower percentage than what is expected by Mendelian genetics. These mice die, however, right after birth. P0.5, postnatal day 0.5.

Asb2 Removal from the Anterior Heart Field Leads to Double Outlet Right Ventricle) in Mice {#sec2.6}
------------------------------------------------------------------------------------------

To determine the cardiac defects of the AHF-Cre.Asb2^fl/fl^.Flna^fl/+^, we examined these mice at e16.5--e17.5 after the completion of cardiac morphogenesis but prior to the perinatal mortality associated with this genotype. Five litters were analyzed. [Figure 6](#fig6){ref-type="fig"}A shows the survival rate of these mice at E16.5. Gross examination of these hearts revealed that both the aorta and the pulmonary artery originate in the RV ([Figure 6](#fig6){ref-type="fig"}B, middle panel, yellow circle). In contrast, both the control hearts ([Figure 6](#fig6){ref-type="fig"}B, left panel) and those with AHF-Cre.Asb2-Flna double mutant ([Figure 6](#fig6){ref-type="fig"}B, right panel) were grossly normal with the pulmonary artery originating in the RV and the aorta originating in the LV. Serial sections of mutant and control hearts ([Figure 6](#fig6){ref-type="fig"}C) further confirm that the AHF-Cre.Asb2^fl/fl^.Flna^fl/x^ mice have DORV ([Figure 6](#fig6){ref-type="fig"}C middle panel, yellow oval). This is also accompanied by a ventricular septal defect ([Figure 6](#fig6){ref-type="fig"}C middle panel right, indicated by asterisk), a feature commonly associated with DORV in patients with congenital heart disease ([@bib40]). As shown in [Figure 6](#fig6){ref-type="fig"}D, the DORV phenotype appeared to be fully penetrant in the AHF-Cre.Asb2^fl/fl^.Flna^fl/x^ hearts. Notably, the DORV phenotype is corrected in the AHF-Cre.Asb2-Flna double mutant hearts (AHF-Cre.Asb2^fl/fl^.Flna^fl/y^, [Figure 6](#fig6){ref-type="fig"}C lower panel).Figure 6AHF-Asb2 Mutant Hearts Have Double Outlet Right Ventricle and Ventricular Septal Defect(A) Table showing the survival of AHF-Cre.Asb2-Flna double mutant mice at E16.5.(B) E16.5 whole hearts of AHF-Cre.Asb2-mutant embryos with one copy of Flna (AHF-Cre.Asb2^fl/fl^.Flna^fl/x^), AHF-Cre.Asb2.Flna double mutants (AHF-Cre.Asb2^fl/fl^.Flna^fl/fl^), and wild-type control. Note that both the pulmonary artery (PA) and the aorta (Ao) are open in the right ventricle (RV) of the AHF-Cre.Asb2^fl/fl^.Flna^fl/x^ hearts (yellow circle). Scale bar is equivalent to 0.02 mm as indicated.(C) Masson trichrome staining of E16.5 heart sections of control (Wt) (top), AHF-Cre.Asb2^fl/fl^.Flna^fl/x^ (middle), and AHF-Cre.Asb2^fl/fl^.Flna^fl/fl^ (bottom) embryos. Note that both the pulmonary artery and the aorta open in the right ventricle of the AHF-Cre.Asb2^fl/fl^.Flna^fl/x^ hearts (yellow circle, middle panel) but not the Wt or the AHF-Cre.Asb2^fl/fl^.Flna^fl/fl^ hearts. The AHF-Cre.Asb2^fl/fl^.Flna^fl/x^ also have a VSD indicated by asterisk (middle panel, right). Ao, aorta; PA, pulmonary artery; RV, right ventricle; LV, left ventricle; IVS, interventricular septum. Scale bar is equivalent to 250 μm.(D) Number of E16.5 hearts with DORV in Wt, AHF-Cre.Asb2^fl/fl^.Flna^fl/x^, and AHF-Cre.Asb2^fl/fl^.Flna^fl/fl^ embryos. Note that 5/5 Asb2^fl/fl^.Flna^fl/x^ have DORV accompanied by a VSD suggesting 100% disease penetrance in these mice.

Asb2 Is Required for Human Embryonic Stem Cell-Derived Cardiomyocyte Differentiation {#sec2.7}
------------------------------------------------------------------------------------

To further investigate if the requirement for Asb2 for cardiac development is conserved during human cardiomyocyte differentiation, we turned to human embryonic stem cell (hESC)-derived cardiomyocyte *in vitro* differentiation. Both ASB2 variants 1 (Asb2β in mice) and 2 (Asb2α in mice) are expressed at different stages of cardiomyocyte differentiation ([Figure 7](#fig7){ref-type="fig"}A, top and bottom graphs, respectively). Using CRISPR/Cas9 genome editing technology, we then generated ASB2-null hESCs. The guides were designed in exon 2 (targeting variant 1 specifically) or exon 4 (targeting variants 1 and 2) ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Four wild-type (Wt) (received the CRISPR/Cas9 constructs but failed to generate an in/del) and four knockout (KO) lines were generated. The genotype of all lines was confirmed by sequencing (refer to [Transparent Methods](#mmc1){ref-type="supplementary-material"}), and the knockouts were confirmed by qPCR ([Figure 7](#fig7){ref-type="fig"}B, right panel). Wt clones were able to differentiate into beating cardiomyocytes, whereas all four KO lines failed to do so ([Video S2](#mmc6){ref-type="supplementary-material"}, top panels for Wt clones and bottom panels for KO clones). Calcium cycling was also impaired in the Asb2-null derived hESCs ([Video S3](#mmc7){ref-type="supplementary-material"}, left panel for Wt and right panel for KO, and [Figure S3](#mmc1){ref-type="supplementary-material"}B). Two Wt and two KO lines were used for further investigation. qPCR analysis on RNA from cardiomyocytes derived from these cells shows that cardiac Troponin T transcript levels (TNNT2, marker of cardiomyocyte differentiation) are greatly reduced in the KO lines at d15 of differentiation ([Figure 7](#fig7){ref-type="fig"}B, right). On the other hand, both NKX2-5 and MESP1 (markers of cardiac progenitors) are normally expressed at d7 of differentiation ([Figure 7](#fig7){ref-type="fig"}B, left). This was further confirmed at the protein level by immunostaining that shows great reduction in cardiac Troponin T (red) expression at d15 ([Figure 7](#fig7){ref-type="fig"}D) and normal NKX2-5 levels (green) at days 15 and 8 ([Figures 7](#fig7){ref-type="fig"}C and 7D, respectively). These data suggest that Asb2-null hES cells can commit to the cardiac lineage but arrest in differentiation prior to the generation of functional cardiomyocytes.Figure 7ASB2 Is Essential for Human Embryonic Stem Cell (hESC)-derived Cardiomyocytes Differentiation(A) qPCR analysis of RNA from hESC-derived cardiomyocytes at different stages of differentiation. Note that both ASB2 variants are expressed at the different stages. N = 4 for D0, n = 5 for all other stages. Data are represented as mean ± SEM.(B) qPCR analysis of RNA extracted from two different wild-type (Wt) clones and two ASB2 mutant (KO) clones d7 (left) and d15 (right) differentiated hESCs. Note reduced Troponin T (differentiation marker) transcripts in the mutants at d15 and no difference in MESP1 and NKX2-5 (cardiac progenitor markers) levels at d7. N = 3 per sample for d7 and N = 4 per sample for d14. Data are represented as mean ± SEM. ∗ = p \< 0.05. Two-way ANOVA was used for analysis using GraphPad Prism. p \< 0.05 is considered statistically significant.(C and D) Immunostaining of d8 (C) and d15 (D) differentiated Wt and ASB2 mutant cells (KO). Note reduced Troponin T (red)-positive mutant cells at d15 but no difference in NKX2-5 (green) levels between Wt and mutant cells at both stages. DAPI (blue) marks all nuclei. Scale bar is equivalent to 8 μm in (C) and 10 μm in (D) as indicated.

Video S2. Movies of Randomly Selected hESC-CM Clusters (WT: Top, KO: Bottom), Related to Figure 7Note the inability of the KO clusters to beat.

Video S3. Movies of Randomly Selected hESC-CM Clusters (WT: Left, KO: Right) Incubated with the Fluo-4 AM Calcium Indicator Prior to Imaging, Related to Figure 7Note the inability of the KO clusters to cycle calcium.

We then examined if ASB2 regulation of the TGFβ/SMAD signaling seen in mice hearts is conserved in the human cells. As discussed above, upon TGFβ/Smad activation, the signaling transducer Smad4 is translocated to the nucleus to activate downstream targets. [Figure 8](#fig8){ref-type="fig"}A shows an increase in nuclear SMAD4 (green) in the ASB2-null hES-derived cardiomyocytes. The nuclear versus total SMAD4 was quantified ([Figure 8](#fig8){ref-type="fig"}A, right graph) showing that nuclear SMAD4 signal is doubled in the ASB2-null cells, whereas total Smad4 levels remain the same. Western blot analysis on total protein extracts from these cells also confirms significant increase in both SMAD4 and pSMAD2 protein levels ([Figures 8](#fig8){ref-type="fig"}B and 8C). This further confirms that the TGFβ/SMAD signaling pathway is activated in Asb2-null cardiomyocytes.Figure 8ASB2 Is an Upstream Regulator of TGFb/SMAD Pathway in hESC-derived Cardiomyocytes(A) Immunostaining of d15 Wt and ASB2 mutant (KO) hESC-derived cardiomyocytes using SMAD4-specific antibody (green). Note reduced level of nuclear but not total mean fluorescence intensity of SMAD4-positive cells in the KOs (quantification graphs on the right). DAPI (blue) marks all nuclei. Scale bar is equivalent to 75 μm in the first column and 25 μm in the second and third columns as indicated. ∗: p \< 0.005 significant versus Wt. Unpaired t test was used for analysis using GraphPad Prism.(B and C) (B) Western blot analysis of Wt and ASB2 mutant (KO) hESC-derived cardiomyocytes using SMAD4, SMAD2, and pSMAD2 antibodies. Note increase of SMAD4 and pSMAD2 in the mutant clones. Data are representative of three separate experiments (C) Quantification of the western blot analysis in (B). Data are average of quantification from three separate experiments. ∗: significant versus Wt1 and Wt2. p \< 0.05 is considered statistically significant. One-way ANOVA was used for analysis using GraphPad Prism.

Discussion {#sec3}
==========

In this study, we provide strong evidence for the role of Asb2 in controlling heart morphogenesis partly through its regulation of the actin-binding protein, Filamin A (Flna), and Tgfβ/Smad signaling. We further show that this regulation is part of the DORV disease pathogenesis.

Using CUBIC clearing technique combined with immunofluorescence and confocal microscopy, we show that the Asb2-mutant hearts have shorter heart tubes and do not form the fully looped helical structure. RNA-seq analysis also reveals that a number of genes that have been linked to cardiac looping defects are altered in the Asb2-mutant hearts. Recent morphological analysis of Asb2 null embryos suggested that cardiac looping in the total body null is largely intact ([@bib35]). To examine this more carefully, we exploited recent advances in tissue clearing coupled to optical sectioning and 3D reconstruction. This analysis of the intact embryos, however, allows us to refine these findings and to examine the Asb2 mutant hearts more thoroughly and at a slightly later point in development. Although the hearts do start to loop, they arrest early on before making it to the helical fully looped heart. Measurement of the heart tube length reveals shorter heart tubes in the mutant hearts, which could explain the inability of the heart to fully form the helical structure. These data further reveal the important role of Asb2 regulation of cardiomyocyte differentiation on the normal growth of the heart tube. We show that the CUBIC technique combined with immunofluorescence/confocal microscopy has distinct advantages over traditional morphological analysis for the phenotypic analysis of mouse embryos and allows for the detection of subtle phenotypes and morphological abnormalities.

Our data further reveal that Filamin A (Flna) is aberrantly overexpressed in the Asb2-mutant cardiomyocytes that normally do not express Flna protein. This is consistent with the data that Metais et al. reported. We also show that this regulation is dose dependent. We further show that Asb2-Flna regulate Tgfβ-Smad signaling. Nuclear pSmad2 is overexpressed in the Asb2-mutant hearts consistent with the upregulation of this signaling pathways. Its levels are restored to normal in the Asb2.Flna double mutants further showing that Asb2 regulates SMAD signaling through the Flna pathway. RNA-seq analysis also reveals that regulation of the Tgfβ-Smad pathway in the Asb2-mutant hearts and the Foxa genes, which are downstream effectors of the Tgfβ/Smad signaling ([@bib55]), is in fact restored to normal in the Asb2-Flna double mutants. Flna has been previously shown to associate with Smad2 signaling ([@bib49]). Moreover, Tgfβ/Smad2/3 signaling is impaired in the multivalve degeneration disorder, X-linked myxomatous valvular dystrophy, in which FLNA mutations were reported ([@bib15], [@bib39]). Our data provide further evidence for regulation of the Tgfβ/Smad cycle by Flna and show that Asb2 is upstream of this regulatory pathway in the developing heart.

Using human embryonic stem cell (hESC)-derived cardiomyocytes, we further show that the Asb2 role in embryonic heart differentiation is conserved in humans. Although ASB2-null hESCs are able to form cardiac progenitor cells (marked by expression of MESP1 and NKX2-5), they have an impaired ability to differentiate into beating TNNT+ cardiomyocytes. It is important to note here that the difference between Troponin T levels in the Asb2-null hESCs and the Asb2 mutants *in vivo* could be due to the total knockout in the cells that is more severe than the conditional *in vivo* knockout. Additionally, the cell system lacks signaling coming from the endocardium, which could also explain this difference. These results demonstrate that, in human PSCs differentiating *in vitro*, ASB2-mediated targeted degradation is required for the differentiation from NKX2-5+ progenitors to beating TNNT+ cardiomyocytes and that deletion of ASB2 results in a differentiation arrest at the progenitor stage. Moreover, the finding that these cells have increased levels of SMAD4 and pSMAD2, markers of TGFβ/SMAD pathway activation, provides further evidence that ASB2 is an upstream regulator of the TGFβ/SMAD pathway during the differentiation of human cardiomyocytes. These considerations become increasingly important given the potential of pluripotent stem cell-derived CMs to serve as a renewable cell source for cardiac regeneration in the injured heart.

Given that Flna is a direct target of Asb2 that is aberrantly upregulated in Asb2-mutant cardiomyocytes, we then investigated whether Asb2 cardiac mutant embryonic lethality can be rescued by the concurrent deletion of Flna. Accordingly, we generated AHF-Cre.Asb2^fl/fl^.Flna^fl/y^ double mutants. Our data show that, as opposed to the AHF-Cre.Asb2^fl/fl^ single mutants that die by E11.5, the AHF-Cre.Asb2^fl/fl^.Flna^fl/y^ double mutants are born with the expected Mendelian ratios ([Figure 5](#fig5){ref-type="fig"}B) but die shortly after birth. This suggests partial rescue of lethality seen in the AHF-Cre.Asb2^fl/fl^ mutant hearts. Of note, we also generated Nkx2-5^+/Cre^.Asb2^fl/fl^.Flna^fl/Y^ double mutants that did not rescue the Asb2 lethality ([Figure S2](#mmc1){ref-type="supplementary-material"}A), suggesting a greater Asb2 dependency or a more complex phenotype in these mice. These findings are not surprising owing to earlier and broader expression domain of the Nxk2-5^Cre^ compared with the AHF-Cre line. Moreover, AHF-Asb2-mutant mice with one Flna allele (AHF-Cre.Asb2^fl/fl^.Flna^fl/x^) sometimes also survive to P0, albeit at significantly lower than expected ratios ([Figure 5](#fig5){ref-type="fig"}B). Not only do these results suggest a dose dependency of Asb2 and its target Flna but they also allow us to identify DORV associated with ventricular septal defect (VSD) as a penetrant cardiac phenotype. More interestingly, this phenotype was rescued when Flna was abrogated by the concurrent deletion of Flna showing that both Asb2 and Flna play a functional role in the pathogenesis of DORV.

During cardiac development, the heart first forms as a primitive heart tube that then elongates and starts to loop by addition of cells from the anterior, posterior, and second heart field at both the venous and arterial poles. At the onset of looping, left-right asymmetry in the heart becomes morphologically evident and any defects in this process can lead to complex congenital heart problems, including DORV and VSDs ([@bib45]). The heart is the first organ to break the left-right symmetry in the developing embryo, and it has been shown that the actin-cytoskeleton is fundamental for laterality and modulation associated with heart looping. It was shown to provide the built-in mechanism required for cells to acquire left-right asymmetry ([@bib30], [@bib56]). Abnormalities in the control of construction of the cytoskeleton has been previously shown to result in looping defects and ultimately lead to congenital heart problems ([@bib27], [@bib30]). Our data and the data from Metais et al. provide solid evidence for the Asb2-Flna regulation of the actin cytoskeleton during heart morphogenesis ([@bib35]). Our data extend this regulation to show that it is important for normal heart tube and OFT development and, if perturbed, leads to DORV and VSD in the developing mammalian heart. Additionally, we suggest a mechanism where Asb2 downregulation leads to abnormal overexpression of Flna that ultimately leads to increased activity of the Tgfβ/Smad2 signaling in the myocardium thus causing growth/elongation defects and DORV in the mammalian heart. Indeed, prior reports have implicated the Tgfβ superfamily and Smad2/3 in left-right asymmetry, and Tgfβ2 mutant mice have been shown to develop DORV and die right after birth ([@bib1], [@bib48], [@bib60]). In humans, a missense mutation in Flna (c.5290G\>A (p.A1764T) has been reported in a patient with DORV ([@bib8]). Since missense mutations can result in both loss and gain of function, future studies will be required to determine the effect of this mutation on Flna expression and function. Thus, our data demonstrate a link between targeted protein turnover and the development of DORV and highlights the potential of the ASB2/FLNA axis as a diagnostic, prognostic, and/or therapeutic target for patients with DORV.

Limitations of the Study {#sec3.1}
------------------------

Although our data show that the role of Asb2 in heart morphogenesis is conserved between mice and human, a limitation is that the *in vivo* murine system is a conditional knockout compared with the total knockout in the human cells system. Additionally, as we know, a cross talk between the endocardium and the myocardium occurs during heart morphogenesis, and this again is lacking in our human cell system.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

RNA-seq data have been deposited in NCBI\'s Gene Expression Omnibus (GEO). The accession number for the RNA-seq data reported in this paper is GEO: [GSE145495](ncbi-geo:GSE145495){#interref20}.
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Document S1. Transparent Methods and Figures S1--S3Table S1. Ingenuity Pathway Analysis of the Differentially Regulated Genes in the Nkx2-5^+/Cre^, Related to Figure 3Asb2-null hearts versus control showing the regulated pathways.Table S2. Ingenuity Pathway Analysis of the Differentially Regulated Genes in Nkx2-5^+/Cre^, Related to Figure 3Asb2-null hearts versus control showing the upstream regulators whose downstream targets are differentially regulated in our dataset.Table S3. Ingenuity Pathway Analysis of the Upstream Regulators in the Set of Genes That Are Corrected in the Differentially Regulated Genes of the Nkx2-5^+/Cre^, Related to Figure 3Asb2-Flna double null hearts compared with the Nkx2-5+/Cre.Asb2-null hearts.
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